Raymond James analyst Steven Seedhouse maintains $Gilead Sciences (GILD.US)$ with a buy rating, and adjusts the target price from $93 to $103.
According to TipRanks data, the analyst has a success rate of 41.4% and a total average return of 10.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Gilead Sciences (GILD.US)$'s main analysts recently are as follows:
The company experienced a sales surge, propelled by robust performance within its HIV product line and higher-than-anticipated revenue from Veklury. The firm noted that the company's HIV business delivered a solid quarter characterized by sustained volume expansion and a beneficial product mix.
The company surpassed the third-quarter expectations, bolstered not only by Veklury but also by the performance of Biktarvy.
The company is perceived to be undergoing significant changes, focusing on its core strength as a pioneer in the field of antivirals. This shift is exemplified by the development of lenacapavir, which has the potential to become a cornerstone in HIV therapy and to broaden the scope of PrEP to a wider audience. The expansion of the PrEP market beyond traditional demographics is seen as an opportunity for growth. Furthermore, the company's oncology segment is advancing with robust growth in TRODELVY and a collaboration with a partner that is poised to deliver a top-tier CAR-T therapy for multiple myeloma.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
瑞傑金融分析師Steven Seedhouse維持$吉利德科學 (GILD.US)$買入評級，並將目標價從93美元上調至103美元。
根據TipRanks數據顯示，該分析師近一年總勝率為41.4%，總平均回報率為10.2%。
此外，綜合報道，$吉利德科學 (GILD.US)$近期主要分析師觀點如下：
該公司的銷售激增受到HIV產品線強勁表現和來自Veklury的高於預期的營業收入推動。該公司指出，HIV業務表現出色，成交量持續擴張，產品組合有利，這一季度表現穩固。
該公司超過了第三季度的預期，不僅受Veklury的推動，還得益於Biktarvy的表現。
該公司被認爲正在經歷重大變革，專注於作爲抗病毒藥物領域先驅的核心優勢。這一轉變體現在lenacapavir的開發上，該藥有望成爲HIV治療的支柱，並擴大PrEP的受衆範圍。PrEP市場超越傳統人群的擴展被視爲增長機會。此外，該公司的腫瘤學部門正在與夥伴合作，致力於爲多發性骨髓瘤提供頭號CAR-t療法，並且TRODELVY的強勁增長也在持續推進。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
